Research Article

Dietary Immunosuppressants do not Enhance UV-Induced Skin Carcinogenesis, and Reveal Discordance between p53-Mutant Early Clones and Carcinomas

Pieter Voskamp¹, Carolien A Bodmann¹, Gudrun E Koehl², Heggert G. Rebel¹, Marjolein G.E. Van Olderen¹, Andreas Gaumann³, Abdoel El Ghalbzouri¹, Cornelis P. Tensen¹, Jan N. Bouwes Bavinck¹, Rein Willemze¹, Edward K. Geissler², and Frank R. De Gruijl¹

Abstract

Immunosuppressive drugs are thought to cause the dramatically increased risk of carcinomas in sun-exposed skin of organ transplant recipients. These drugs differ in local effects on skin. We investigated whether this local impact is predictive of skin cancer risk and may thus provide guidance on minimizing the risk. Immunosuppressants (azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, and rapamycin) were assessed on altering the UV induction of apoptosis in human skin models and of p53 mutant cell clones (putative tumor precursors) and ensuing skin carcinomas (with mutant p53) in the skin of hairless mice. Rapamycin was found to increase apoptosis (three-fold), whereas cyclosporine decreased apoptosis (three-fold). Correspondingly, a 1.5- to five-fold reduction ($P = 0.07$) or a two- to three-fold increase ($P < 0.001$) was found in cell clusters overexpressing mutant p53 in chronically UV-exposed skin of mice that had been fed rapamycin or cyclosporine, respectively. Deep sequencing showed, however, that the allelic frequency (≈5%) of the hotspot mutations in $p53$ (codons 270 and 275) remained unaffected. The majority of cells with mutated $p53$ seemed not to overexpress the mutated protein. Unexpectedly, none of the immunosuppressants admixed in high dosages to the diet accelerated tumor development, and cyclosporine even delayed tumor onset by approximately 15% ($P < 0.01$). Thus, in contrast to earlier findings, the frequency of p53-mutant cells was not predictive of the incidence of skin carcinoma. Moreover, the lack of any accelerative effect on tumor development suggests that immunosuppressive medication is not the sole cause of the dramatic increase in skin cancer risk in organ transplant recipients. Cancer Prev Res; 1-10. ©2012 AACR.

Introduction

Organ transplant recipients have a high risk of developing squamous cell carcinomas (SCC) of the skin on sun-exposed areas. In the Netherlands, 40% of renal transplant recipients develop skin cancer within 20 years after transplantation (1), and in Australia the risk is substantially greater (70%; ref. 2). These solar-related (3) skin carcinomas in organ transplant recipients tend to be aggressive and often recur more (4).

Because most UV-induced skin carcinomas are thought to be antigenic and targeted by the immune system (5), transplant-related immunosuppression is perhaps an inescapable side effect of organ transplantation treatment. Indeed, some commonly used immunosuppressants directly promote cancer growth or affect antitumorigenic responses, such as apoptosis (6–8). The actions of immunosuppressive drugs used in transplantation practice differ substantially. For example, azathioprine and mycophenolate mofetil, or rather their metabolites 6-mercaptopurine and mycophenolic acid, respectively, inhibit purine synthesis, and thus T-cell proliferation (9). Cyclosporine and tacrolimus block T-cell activation through calcineurin inhibition (9). Rapamycin inhibits mTOR that impairs interleukin (IL)-2 production and therefore T-cell proliferation (9–12). Important for the present discussion is that some of these immunosuppressants also affect skin cells, contributing to carcinoma risk. For instance, azathioprine and cyclosporine adversely affect DNA repair and cyclosporine also impairs apoptosis (6, 7, 13), which are important mechanisms that help protect against UV skin carcinogenesis; azathioprine further enhances DNA damage by photosensitization (8). Indeed, azathioprine and cyclosporine speed...
up UV carcinogenesis in hairless mice (7, 14). However, not all immunosuppressants necessarily promote cancer development. While mycophenolate mofetil has some capacity to reduce tumor cell proliferation (15, 16), rapamycin exhibits impressive inhibitory effects on cancer development. Rapamycin inhibits angiogenesis and tumor cell proliferation (15, 17, 18), leading to impaired inoculated tumor growth in mice and de novo tumor development in a p53-null mice (19). Interestingly, azathioprine-treated transplant patients have more mutant p53-overexpressing cell clusters in precursor skin lesions than immunocompetent patients with skin carcinomas (20); this finding contrasts with results in rapamycin-fed mice that develop fewer mut-p53 cell clusters than control mice (21). Whether this effect is related to the rapamycin-induced increase in apoptotic responses we have observed after UV irradiation (21), is not clear. From a clinical perspective, recent trials do suggest rapamycin treatment decreases the development of skin carcinomas in organ transplant recipients (22, 23).

Here, we compared the tumorigenic properties of an array of commonly used immunosuppressants in experiments using human skin and mouse models. We systematically compared the impact of the immunosuppressants on epidermis and its responses to UV exposure (most specifically, apoptosis) in human skin equivalents (HSE). In addition, we linked these in vitro results to local effects of the immunosuppressants on UV-induced early formation of mut-p53 cell clusters, and overall effects on subsequent formation of skin tumors in a hairless mouse model. These experiments allowed us to establish whether local effects of immunosuppressants on UV-induced apoptosis and p53 mutations in the skin are predictive of skin cancer risk. In contrast to our expectations, none of the immunosuppressants enhanced the rate at which skin tumors developed in mice.

Materials and Methods

Human skin equivalents

Generation of HSEs was conducted as described earlier (24). In brief, keratinocytes and fibroblasts were isolated from surplus breast skin obtained from cosmetic surgery of 2 donors (obtained in accordance with the Dutch Law on Medical Treatment Agreement). A total of 80 × 10⁶ fibroblasts were seeded into acetic acid–extracted rat-tail collagen deposited on filter inserts (product no. 3414; Corning). The fibroblast-populated matrices were cultured for a week in standard fibroblast medium. These matrices were subsequently seeded with 5 × 10⁵ low-passage normal human epidermal keratinocytes and incubated with keratinocyte medium. Medium was refreshed twice a week. After 2 weeks of air-exposed culture, the HSEs were processed for analysis.

Supplements/chemicals

Immunosuppressants dissolved in absolute dimethyl sulfoxide (DMSO) were added to the HSEs at physiologically relevant concentrations (25, 26); rapamycin (Calbiochem) at 10 or 100 nmol/L, 6-mercaptopurine (Sigma-Aldrich) at 50 or 500 nmol/L, cyclosporine (Sigma-Aldrich) at 100 nmol/L or 1 μmol/L, and mycophenolic acid (Sigma-Aldrich) at 1 or 10 μmol/L, at 0.1%(v/v). 6-Mercaptopurine and mycophenolic acid are used as they are the active metabolites of azathioprine and mycophenolate mofetil, respectively (21, 27). For effects on morphology, HSEs were supplemented with immunosuppressants or DMSO only (as vehicle control) during the air-exposed culture. For effects on the response after UVB irradiation, HSEs were supplemented with immunosuppressants for 2 days before UVB irradiation.

The mice

SKH-1 hairless albino mice (Charles River) entered the experiment at 8 to 16 weeks of age; both male and female mice were used equally divided over the groups. The animals were housed individually under a 12-hour light–12-hour dark cycle at 23°C. Experimental chow was supplied in ample amounts (60 g/mouse/wk), and drinking water was available ad libitum. Cage enrichment was absent to prevent shielding of the animals from UV exposure. All experiments were carried out in accordance with legislation and approval of the center’s ethics committee for animal experiments.

Groups on diets with admixtures of immunosuppressants

To avoid repeated intraperitoneal injections or oral gavage to administer the immunosuppressants, admixtures of the drugs to standard mouse chow were used (Sniff GmbH; ref. 28). For cyclosporine, mycophenolate mofetil and rapamycin dosages in the food were used that resulted in long-term average blood levels in the mice that were similar to the high-end average blood levels in renal transplant patients (cyclosporine at 150 mg/kg in food: 800 ng/mL in blood, mycophenolate mofetil at 660 mg/kg: 2.9 μg/mL mycophenolic acid, rapamycin at 20 mg/kg: 50 ng/mL; mice of 25–35 g body weight ate 5–7 g per day). Avoiding toxicity, tacrolimus and azathioprine were admixed at maximal long-term tolerable dosages (tacrolimus 20 mg/kg: 3.2 ng/mL, azathioprine 30 mg/kg: subanemic white blood cell count). Six diet groups were formed: rapamycin (n = 26), mycophenolate mofetil (n = 22), cyclosporine (n = 24), tacrolimus (n = 24), azathioprine (n = 26), and control groups (each n = 26) fed the standard chow without admixtures (n includes 12 mice sacrificed to score mut-p53 cell clusters, see later). The tumorigenesis experiment was carried out in 3 parts, (i) rapamycin and cyclosporine, (ii) azathioprine and tacrolimus, and (iii) mycophenolate mofetil, each with a control group on chow without admixture. No apparent differences in food intake and body weights were observed between the diet groups.

UVB irradiation

Mice. The 6 groups of albino hairless SKH11 mice were started on their respective diets 1 week before subjecting them to a regimen of daily UV exposure. TL-12/40W tubes (Philips; 54% output in UVB: 280 to 315 nm—and 46% output in UVA: 315 to 400 nm) were used for daily UV exposure. The lamps were mounted over the cages with grid
covers to allow undisturbed exposure of the mice. The lamps were automatically switched on from 12.30 to 12.50 hours. The threshold dose for a sunburn reaction (minimal edema dose, MED) in the hairless SKH-1 mouse was approximately 500 J/m² UV under these lamps. The lamps were dimmed both electronically and by insertion of perforated metal sheets to expose the mice daily to 250 J/m² of UV radiation (0.5 MED).

HSEs. Skin models were also exposed to 1.4 kJ/m² UV from TL-12/20W tubes at 2.8 W/m².

UVA irradiation of azathioprine-fed mice

Pigmented hairless mice were acquired by 2 rounds of breeding C57BL/6 into SKH1 background. These (F2) mice were put on azathioprine (n = 12) or control diet (n = 13) 1 week before subjecting them to a regimen of daily UVA exposure. Cleo Professional S R tubes (Philips; 1.4% of output in UVB: 280 to 315 nm—and 98.6% in UVA: 315 to 400 nm) were used for irradiation. MED was determined by exposing mice to 7, 14, 21, or 28 kJ/m² UV (different exposure times were attained by taping off different parts of the dorsal skin). Mice were daily irradiated at 14 kJ/m² (1 MED) in the UVA carcinogenesis experiment.

Tumor assessment

The mice were inspected weekly for tumors, which were registered for each mouse individually on maps (recording number, location, size, and form). For presentation in a single graph of the tumor induction data in Kaplan–Meier plots, the 3 experiments were adjusted to equal median latency times in the control groups (a time shift of maximally 2 weeks, with an average of 8 days). Upon removal of animals from the experiment, tumors and normal skin were isolated for further analysis as described later.

Epidermal sheet preparation and mutant-p53 immunostaining in epidermal sheets

For quantification of mut-p53 cell clusters, 4 SKH1 mice were taken from each diet group after 4, 7, or 10 weeks of UV exposures. Within 24 hours after the last irradiation, mice were killed and pieces of dorsal skin of 11 mm × 34 mm were excised and treated with a 100 µg/mL thermolysin solution, after which the epidermal sheet was separated from the dermis. The procedure of epidermal sheet preparation and subsequent immunostaining and analysis, described elsewhere (29), was followed with 2 modifications: antigen retrieval in 10 mmol/L citrate buffer in an autoclave at 5 minutes, 110°C and mutant-p53 antibody diluted 1:250 (Pab240, Thermo Fisher Scientific). A 1 to 2 mm wide mid-dorsal strip of the epidermal sheets was collected per mouse and used for DNA isolation (QiAamp, Qiagen). Counts of mut-p53–positive cell clusters outside the range of 6-fold over or under the median (in cohorts of 4 mice) were rejected as outliers (with the exception of “0” if the lower limit was less than 1) to produce Fig. 2; this led to exclusion of 9 of 84 measurements from this graph. However, none of the measurements were excluded from statistical tests (see later).

P53 mutation hotspot PCR and deep sequencing

DNA from the murine epidermal strips of 4 mice per group was mixed equimolarly and used in a PCR reaction amplifying the p53 gene from codon 263 to 276, containing the mutational hotspots at codons 270 and 275. The forward primer contained a sequence-specific part and an adapter sequence at the 5’ end of the primer. The reverse primers were unique for each group containing a sequence-specific part, an index sequence, and an adapter sequence (Supplementary Table S1). Primers were high-performance liquid chromatography (HPLC)-purified (Integrated DNA Technologies). PCRs were conducted using high fidelity Phusion enzyme (Finnzymes) in a volume of 40 µL with the following program: 98°C for 30 seconds, then 28 cycles of 98°C for 10 seconds, 64°C for 15 seconds, 72°C for 15 seconds, closing the program with 72°C for 10 minutes. PCR products were run on a 1.8% agarose gel, and stained with SYBR Gold (Invitrogen), after which bands containing the amplicons were excised on a Dark Reader not emitting UV (Clare Chemical Research) and purified using QIAquick (Qiagen) spin columns. Amplicons were analyzed in one lane of an Illumina Sequencer HiSeq2000 (Illumina). Reads were filtered for high-quality reads containing only bases that were called with a minimal fidelity of 99.9% (phred-score ≥ 30). Index sequences were used to distinguish the different samples. For the numbering of the bases, the p53 transcript with ID ENSMUST00000108658 from Ensembl was used as reference.

Histology and immunohistochemistry

Biopsies were fixed in 4% formaldehyde, dehydrated, and embedded in paraffin or snap-frozen in liquid nitrogen. Stainings for keratins 10, 16, 17 (K10, K16, and K17), and Ki-67 were conducted on formalin-fixed and paraffin-embedded sections (5 µm) of skin models, mouse skin or tumors. Immunohistochemical analysis of active caspase-3 was conducted on frozen sections (5 µm), which after sectioning were fixed in methanol/acetone (1:1) for 10 minutes. Hematoxylin and eosin (H&E) staining was conducted on deparaffinized sections for tumor staging. Staging of tumors from each group was conducted blindly by a pathologist (A. Gaumann) who is experienced in mouse and human pathology, including diagnosis of actinic keratoses as proper precursors of SCCs. Antibody retrieval for paraffin-embedded sections was conducted by autoclaving the sections in 10 mmol/L citrate buffer (pH 6.0) for 10 minutes at 110°C. The primary antibodies used for immunohistochemistry are listed in the Supplementary Table S2. After overnight incubation with the primary antibody at 4°C, sections were stained using standard protocols with 3-amin-9-ethylcarbazole, substrate of peroxidase.

Estimate of proliferation index

The percentage of Ki-67–positive nuclei in the basal and immediate supra-basal layer was used to determine the proliferation index. A minimum of 100 cells were counted using light-microscopy in 3 different regions in each section.
**Statistical tests**

Kaplan–Meier plots of tumor-free survival were tested for differences by $\chi^2$ statistics (Graphpad Prism 5.0). Differences in tumor yields were analyzed with randomized block one-way ANOVA, with Bonferroni as post hoc test (Graphpad Prism 5.0). Differences in number of mutant p53 cell clusters per treatment (without outlier removal) were calculated in a general linear model multivariate analysis with least significant difference as post hoc test. Differences in Ki-67–positive cell percentages in HSEs were calculated with one-way ANOVA and Dunett as post hoc test. Differences in active caspase-3–positive cell fractions in HSEs were calculated with a one-way ANOVA and Bonferroni as post hoc test. $P$ value less than 0.05 was taken to indicate a significant difference. SPSS 16.0 was used for all statistical analyses of immunohistochemical stainings.

**Results**

**Rapamycin affects epidermis in HSE**

From the moment of air exposure, HSEs were cultured with immunosuppressants added to the medium for 2 weeks: rapamycin, tacrolimus, mycophenolic acid, 6-mercaptopurine, cyclosporine, or DMSO (vehicle). Only rapamycin was found to affect the epidermis that developed in the HSE: 3 to 4 epidermal cell layers were formed instead of 7 to 8 (Fig. 1). Rapamycin treatment resulted in a decreased proliferation index (from 43% to 22% and 11% with 100 and 10 nmol/L rapamycin, respectively; $P < 0.05$; Supplementary Fig. S1). Hyperproliferative markers K16 and K17 showed a decreased expression (Fig. 1), whereas expression of the suprabasal differentiation marker K10 remained unaffected (data not shown).

**Cyclosporine decreases and rapamycin increases the active caspase-3–positive cell fraction in HSE after UV irradiation**

To examine the effects of immunosuppressants on apoptosis, HSEs from 2 donors were irradiated with UV (1.4 kJ/m$^2$) 2 days after supplementation of immunosuppressants to the media. The percentage of active caspase-3–positive cells 24 hours after irradiation was determined by immunohistochemistry. Of the 5 immunosuppressants, only rapamycin at 10 and 100 nmol/L increased the percentage of active caspase-3–positive (supra-)basal cells (average 20%; SEM = 4% vs. 7%; SEM = 6% in controls) in skin models of the donor with a low-apoptotic response, whereas only cyclosporine at 1 µmol/L was found to decrease the apoptotic percentage (35%; SEM = 10% vs. 100%; SEM = 0% in controls) in skin models of the donor with a high-apoptotic response.
Cyclosporine and azathioprine increase numbers of mut-p53 cell clusters

Because of their limited lifespan, HSEs are not suitable for generating mut-p53 cell clusters. Therefore, we examined the effects of immunosuppressants on generation of mut-p53 cell clusters in mice. Hairless mice were fed with immunosuppressants admixed to the chow at dosages resulting in blood levels that are at the high end of the range of typical blood levels in renal transplant recipients. Because of toxicity of tacrolimus and azathioprine, dosages of these drugs were limited to maximal long-term tolerable levels. The mice were daily irradiated with 0.5 MED UVB for 4, 7, or 10 weeks, at which time numbers of mut-p53 positive cell clusters were determined. Cyclosporine and azathioprine treatment increased the number of mut-p53 positive cell clusters (P < 0.001 and P < 0.05, respectively; Fig. 2). Rapamycin tended to inhibit their formation at all time points (P = 0.07). The proliferation index of dorsal skin from 4 week--irradiated mice was not affected by any of the immunosuppressants (data not shown). For comparison with p53 mutational frequencies (described later), we determined in 10 week--irradiated control mice that mut-p53 cell clusters covered 6% of surface area of epidermal sheets bordering the epidermal strip that was removed for mutational analysis.

Frequency of p53 mutations in UV-exposed skin

The question arose whether the number of mut-p53 cell clusters corresponded with the frequency of mutated alleles in the p53 gene in the epidermis. To answer this question, DNA from epidermal strips of mice UV-irradiated for 10 weeks and unirradiated control mice was used as template to amplify part of the p53 gene containing 2 mutational hotspots (codons 270 and 275). PCR products (pooled for 4 mice per group) were analyzed by deep-sequencing, with a sequencing depth between 2 and 8 million for the different samples. Three mutations were common in samples of the UV-irradiated mice: 808C>T = aa270 R>C, 823C>T = aa275 P>S, 824C>T = aa275 P>L, with numbers cumulating to a total between 4.6% and 6.6% of the PCR products; samples from unirradiated mice contained these mutations far less frequently at 0.03% (Fig. 3). There were no clear differences in mutational frequencies between the samples from different immunosuppressive treatments and controls.

Cyclosporine delays tumor induction and rapamycin inhibits tumor growth

To examine the effects of immunosuppressants on UVB-induced tumor formation, mice were fed immunosuppressants in their diets and they were daily exposed to 0.5 MED of UV. Tumor development was assessed weekly. Cyclosporine feeding resulted in increased tumor latency times for tumors more than 1 mm (Fig. 4A). Confirming our earlier results (28), rapamycin-fed mice showed no change in onset of small tumors (diameters around 1 mm) but did show a lowered rate of formation of larger tumors, that is, an inhibition of tumor outgrowth. Rapamycin and cyclosporine groups showed significantly lower yields of tumors more than 4 mm as compared with controls (P < 0.01 and P < 0.001, respectively; Fig. 4B). Near the end of the experiment, several mice had to be taken out of the different groups because they extensively scratched their tumors. After 155 days, 7 of 12 mice of the
cyclosporine group were still in the experiment compared with 9 of 14 mice in the control group. None of the other immunosuppressants in the food of the mice seemed to affect the onset or outgrowth of the UV-induced tumors. Histopathology showed all tumors more than 4 mm to be SCCs. No effect of immunosuppressive drugs on tumor type or grading was found.

Azathioprine did not affect UVA-induced tumor induction

To assess whether azathioprine sensitizes mice for UVA carcinogenesis (30), mice were put on an azathioprine-containing diet or control diet for 2 weeks. Besides albino mice, pigmented mice were included because there is evidence that melanin may sensitize skin to UV exposure (31), which could conceivably synergize with azathioprine in photosensitization. No effect of immunosuppressive drugs on tumor type or grading was found.

Discussion

In this study, we aimed to establish whether short-term local skin effects of immunosuppressants on UV-induced apoptosis and medium-term effects on \(p53\) mutations are predictive of the risk of skin cancer development. Of the immunosuppressants tested in this study, rapamycin showed an inhibitory effect on epidermal regeneration and increased UV-induced apoptosis in human skin models, whereas cyclosporine decreased apoptosis. Despite corresponding effects on the formation of clusters of cells over-expressing mutant-\(p53\) in mice—that is, a decrease by rapamycin, an increase by cyclosporine—the effects on tumor onset were discordant. Cyclosporine was unexpectedly shown to delay tumor onset and rapamycin had no effect on tumor onset but inhibited tumor growth. Remarkably, despite high dietary dosages and blood levels (for rapamycin and cyclosporine adequate to maintain allogenic heart grafts in mice; ref. 18) none of the dietary-fed tumors more than 1 or 2 mm (Supplementary Fig. S3). Because some mice started scratching their tumors after 19 weeks in the experiment, they had to be removed from the experiment; as a result, tumor yield data for tumors more than 4 mm could not be measured reliably.

Figure 4. A, tumor-free survival (Kaplan–Meier) plots of the different treatment groups, with different thresholds for tumor detection: diameters more than 1 or 4 mm. B, average tumor yields are shown per mouse for control, rapamycin (Rapa) and cyclosporine (CsA) treatment. Error bars depict SEM. In A and B, CsA vs control >1 mm \(P < 0.01\); in B, CsA and Rapa vs control >4 mm \(P < 0.001\) and \(P < 0.01\), resp. Tac, tacrolimus; Aza, azathioprine; MMF, mycophenolate mofetil.
immunosuppressants increased UV-induced skin carcinogenesis in the mouse model used in this study; an overview of the results is presented in Table 1. Below we discuss the effects of immunosuppressants on UV-responses and the different stages in tumor development, viz. cellular responses in human skin models, mut-p53 cell clusters, p53 mutational frequencies, and tumor development in mice.

In HSEs, we could verify earlier results (6, 32) that rapamycin increased the UV-induced apoptotic response, whereas cyclosporine inhibited this apoptotic response. Epidermal formation in HSE was impaired by rapamycin: resulting in fewer cell layers, a decreased proliferation index (Ki-67) resulting in fewer cell layers, a decreased proliferation index (Ki-67) and reduced expression of hyperproliferation markers (K16 and K17). This decreased proliferation in HSEs may be related to wound-healing problems associated with rapamycin treatment in transplantation patients (33). In HSEs, cyclosporine pretreatment caused a decrease in the apoptotic response after UV irradiation. This decrease in apoptotic response was evident in HSEs with a high percentage of apoptotic cells, leaving the possibility that cyclosporine exerts this effect only at highly apoptotic UV doses, as suggested by Flockhart and colleagues (34).

Cyclosporine and azathioprine increased the formation of mut-p53 cell clusters in mice, whereas rapamycin tended to inhibit mut-p53 cell cluster formation. The lower number of UV-induced mut-p53 cell clusters formed in the skin of rapamycin-treated mice is apparently not due to decreased proliferation, as the fraction of Ki-67–positive cells was not decreased in rapamycin-treated mice. A previous study from our group (20) showed no effect of azathioprine on mut-p53 cell cluster formation in mice, but it should be noted that azathioprine in these experiments was administered by intraperitoneal injections, and variations in counts of these clusters were very large.

Immunosuppressants did not affect the mutational frequency of p53 genes in chronically UV-irradiated skin in mice, as measured by deep sequencing, contrasting with effects on mut-p53 cell cluster formation. On average, 5% of the sequenced alleles were mutated, corresponding to 10% of the cells assuming heterozygous mutations. As the hotspot mutations at codons 270 or 275 comprise about half of the mutations in the p53 gene, the mutational frequency suggests that maximally 20% of the cells in the skin would harbor mutated p53 (if cells harbored more than one mutation in similar percentages as mut-p53 cell clusters, the fraction would come down to about 14%; refs. 29, 35). These results are in agreement with a recent deep sequencing study of human skin from middle-aged individuals revealing that persistent p53 mutations had accumulated in 14% of the epidermal cells (36). The percentage of skin area containing mut-p53 cell clusters in our mice was much lower, approximately 6%. It can therefore be concluded that a minority of the cells harboring a mutated p53 show overexpression of mut-p53 in cell clusters. This indicates that a mutation in p53 is apparently not sufficient to cause overexpression of the p53 protein in mut-p53 cell clusters (21, 37). And tumors may arise from a larger pool of p53-mutated cells than visible in IHC of mutant p53-overexpressing cell clusters. Evidently, the local effects of immunosuppressants in the skin affecting the mut-p53 cell clusters are not paralleled by correspondingly proportional effects on p53 mutations and tumor onset.

None of the immunosuppressants increased UV-induced tumor development, and cyclosporine even delayed tumor onset. Rapamycin had no effect on the development of small tumors, but decreased the outgrowth of tumors. Growth inhibition was reported earlier by our group (28), and the growth inhibition by rapamycin was more prominent in that experiment. Other UV carcinogenesis studies with different treatment schemes have shown either lower tumor yields (38) or higher tumor yields (39) in rapamycin-treated mice, indicating that the precise treatment regimen may be decisive for the outcome of the tumorigenesis experiment. Proliferation of epidermal

### Table 1. Summary of the results obtained for the different immunosuppressants

<table>
<thead>
<tr>
<th></th>
<th>Cyclosporine</th>
<th>Tacrolimus</th>
<th>Azathioprine</th>
<th>Mycophenolate</th>
<th>Rapamycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human skin model</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidermal regeneration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proliferation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apoptosis after UV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proliferation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of mut-p53 cell</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clusters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P53 mutational frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in nontumor epidermis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yield of small tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&gt;1 mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yield of large tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(&gt;4 mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NOTE: —, no effect; ↓, inhibitory effect; ↑, stimulatory effect.
Because most SCCs and actinic keratoses harbor mutations in the p53 gene, p53 mutations are considered to be early events in SCC formation, and therefore mut-p53 cell clusters are thought to be precursors of SCCs (45, 46; Fig. 5A). However, an earlier retrospective study did not find any differences in numbers of mut-p53 cell clusters between skin from patients with solitary versus multiple skin carcinomas (47). As we found that compounds (rapamycin vs. cyclosporine) can have opposing effects on mut-p53 cell clusters and SCC formation, it follows that mut-p53 cell cluster formation cannot be used as a simple indicator of tumor risk. These results open up an alternative perspective on the developmental stages of skin carcinomas, one in which SCC development is independent of mut-p53 cell cluster formation (Fig. 5B).

Using the present mouse model and experimental setup, the effect of the immunosuppressive drugs on tumor risk seems not to be in agreement with the increased skin cancer risk in transplant recipients. Moreover, we did not find consistent links between effects on UV-induced apoptosis, frequency of p53 mutations and the ultimate formation of skin tumors. These discrepancies between the effects on mut-p53 cell clusters and tumors, and the striking overall lack of enhanced UV carcinogenesis in the present mouse experiments imply that the mouse model does not properly emulate skin cancer development in organ transplant recipients. Elucidation of these discrepancies, whether they are caused by an incomplete experimental model (not fully representing organ transplantation with complex immunosuppressive regimens) or physiologic differences between mice and humans, should contribute to a better understanding of the risk of skin carcinogenesis in organ transplant recipients.

Disclosure of Potential Conflicts of Interest
E.K. Geissler has honoraria from Speakers Bureau and is a consultant/advisory board member of Pfizer. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. A. Bodmann, H. G. Rebel, A. Gaumann

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P. Voskamp, H. G. Rebel, A. Gaumann, C. P. Tensen, F. R. DeGruijl

Writing, review, and/or revision of the manuscript: P. Voskamp, G. E. Koehl, A. Gaumann, A. El Ghallabzouri, C. P. Tensen, J. N. B. Bavincik, R. Willemze, E. K. Geissler, F. R. DeGruijl

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P. Voskamp, C. A. Bodmann, G. E. Koehl, M. G. E. Van Olderen


Grant Support

This research was supported by the Dutch Cancer Society, grant number 2007-3910.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 21, 2012; revised November 26, 2012; accepted November 29, 2012; published OnlineFirst December 11, 2012.

References


Published OnlineFirst December 11, 2012; DOI: 10.1158/1940-6207.CAPR-12-0361

www.aacrjournals.org Cancer Prev Res; 2012 OF9

Downloaded from cancerpreventionresearch.aacrjournals.org on June 19, 2017. © 2012 American Association for Cancer Research.
Dietary Immunosuppressants do not Enhance UV-Induced Skin Carcinogenesis, and Reveal Discordance between p53-Mutant Early Clones and Carcinomas

Pieter Voskamp, Carolien A Bodmann, Gudrun E Koehl, et al.


Updated version Access the most recent version of this article at: doi:10.1158/1940-6207.CAPR-12-0361

Supplementary Material Access the most recent supplemental material at: http://cancerpreventionresearch.aacrjournals.org/content/suppl/2012/12/11/1940-6207.CAPR-12-0361.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.